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Although some of the underlying technology for quantifying
protein abundance was introduced almost thirty years ago
[1,2], there has recently been a significant increase in the
development of new tools. Concurrently, tools for analyzing
mRNA expression are becoming more mainstream. The
quantification of both of these molecular populations is not
an exercise in redundancy; measurements taken from
mRNA and protein levels are complementary and both are
necessary for a complete understanding of how the cell
works [3]. Additionally, as mRNA is eventually translated
into protein, one might assume that there should be some
sort of correlation between the level of mRNA and that of
protein. Alternatively, there may not be any significant cor-
relation, which, in itself, is an informative conclusion. 
The two commonly used high-throughput methods for mea-
suring mRNA expression, microarrays and Affymetrix chips,
have both been extensively reviewed elsewhere [4-6]. There
are also two basic methods for determining protein abun-
dance; either based on two-dimensional electrophoresis or on
mass-spectrometric methods (Table 1). We provide a brief
review of these technologies and recent efforts to determine
correlations between quantified protein abundances and
mRNA expression.
Methods for determining protein levels
Two-dimensional electrophoresis
Determining relative protein expression levels by conven-
tional two-dimensional electrophoresis requires isoelectric
focusing, SDS-polyacrylamide gel electrophoresis, staining,
fixing, densitometry, and careful matching of the same spots
on two or more gels. Differentially expressed spots are then
excised and enzymatically digested, and the resulting pep-
tides are identified using mass spectrometry. An attractive
aspect of this approach is the low capital equipment cost, but
a high level of expertise is needed to obtain reproducible
gels, and two-dimensional electrophoresis is generally
limited to proteins that are neither too acidic, too basic, nor
too hydrophobic, and that are between 10 and 200 kDa in
size, so that they are reliably separated on gels. Additionally,
this approach detects only those proteins that are expressed
at relatively high levels and that have long half-lives [7,8]. In
one study using 40 µg yeast lysate, the average protein
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Attempts to correlate protein abundance with mRNA expression levels have had variable success.
We review the results of these comparisons, focusing on yeast. In the process, we survey experimen-
tal techniques for determining protein abundance, principally two-dimensional gel electrophoresis and
mass-spectrometry. We also merge many of the available yeast protein-abundance datasets, using the
resulting larger ‘meta-dataset’ to find correlations between protein and mRNA expression, both
globally and within smaller categories. abundance detected was 51,200 copies per cell, with no pro-
teins detected with abundances less than 1,000 copies per
cell [8]. Given that 1,500 spots were resolved on a 1.0 pH
unit gel [8], several gels covering different pH ranges would
be needed to resolve a whole cell lysate. Given these limita-
tions, conventional two-dimensional electrophoresis tech-
nology has limited potential for large-scale proteome
analysis [8]. 
Two-dimensional fluorescence-difference gel electrophoresis
(DIGE) utilizes mass- and charge-matched, spectrally
resolvable fluorescent dyes (such as Cy3 and Cy5) to label
two different protein samples in vitro prior to two-dimen-
sional electrophoresis. Its main advantage over conventional
two-dimensional electrophoresis is that both the control and
the experimental sample are run in a single polyacrylamide
gel. The samples are then imaged separately but can be per-
fectly overlaid without any ‘warping’ of the gels. This sub-
stantially raises the confidence with which protein changes
between samples can be detected and quantified. Changes in
the relative level of expression of a protein may be detected
that are as little as 1.2-fold for large-volume spots [9].
Because detection is based on fluorescence, DIGE has a large
dynamic range of about 10,000, which permits differential
expression analysis of proteins that are present at relatively
low copy number [9]. The limit of detection of DIGE for
quantifying protein expression ratios is between 0.25 and
0.95 ng protein, which is similar to that for silver staining
[9,10]. In a recent study [11], the relative levels of expression
of approximately 1,050 protein spots were compared in
250,000 laser-dissected normal versus esophageal carci-
noma cells. This analysis identified 58 spots that were
up-regulated by more than three-fold and 107 that were
down-regulated by more than three-fold in cancer cells.
Mass spectrometric approaches
Disease biomarker discovery
Current approaches to discovering protein or peptide
markers of disease involve batch chromatography, matrix-
assisted laser desorption ionization mass spectrometry
(MALDI-MS) and statistical analysis of large numbers of
disease versus normal serum or other biological samples.
Most recent studies have relied on surface-enhanced laser
desorption ionization time-of-flight mass spectrometry
(SELDI-TOF-MS) [12,13]. The SELDI approach [13] involves
using a gold-coated chip with eight or sixteen 2 mm spots
that are modified with chromatographic surfaces (for
example anionic, cationic, hydrophobic, and so on). After
spotting a few microliters of serum, any contaminants and
salt are removed by washing with water, and the target is
dried by adding a MALDI matrix solution, such as α-cyano-4-
hydroxy-cinnamic acid. In a study by Petricoin et al. [14]
SELDI-MS analysis of serum from 50 control and 50 case
samples from patients with ovarian cancer resulted in identi-
fying five peptide biomarkers that ranged in size from 534 to
2,465 Da. The pattern formed by these markers was then
used to correctly classify all 50 ovarian cancer samples in a
masked set of serum samples from 116 patients who included
50 patients with ovarian cancer and 66 unaffected women.
Similar promising results have been reported in studies of
serum samples from breast and prostrate cancer patients
[12,15]. In a recent study [16], which compared the relative
ability of several different statistical approaches to classify
samples based on MS data, the disease biomarker approach
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Table 1
Overview of selected protein profiling technologies
Number of 
Ability to detect many  Approximate  proteins/spots 
Type of labeling  post-translational Biomolecules that are  dynamic range  quantified 
Technology required modifications optimally quantified (and reference) (and reference)
Two-dimensional gel  Silver staining Yes Naturally occurring forms  10 [9] 1,500 [8]
electrophoresis of proteins larger than 10 kDa 
Differential two- In vitro with Cy2, Cy3  Yes Naturally occurring forms  10,000 [9] 1,100 [51]
dimensional fluorescence  or CY5 fluorophores  of proteins larger than 10 kDa
gel electrophoresis (DIGE) at primary amines
SELDI- or MALDI-MS  None Yes Naturally occurring forms  25 Not applicable
disease biomarker discovery  of proteins smaller than 10 kDa
Isotope-coded affinity  In vitro with H1/D or  No Cysteine-containing tryptic  10,000* 496 [18]
tag (ICAT) - LC/MS C12/C13 ICAT reagent  peptides from digests of 
at cysteine  protein extracts
N14/N15 - LC/MS In vivo at nitrogens  Yes Tryptic peptides from digests  10,000 [19] 872 [20]
in amino acids of protein extracts
*Assumed to be similar to that for multidimensional protein identification. Abbreviations: SELDI-MS, surface-enhanced laser desorption ionization mass
spectrometry; MALDI-MS, matrix-assisted laser desorption ionization mass spectrometry; LC/MS, liquid chromatography and mass spectrometry.was extended to a conventional MALDI-MS platform.
Although powerful, the disease biomarker approach does not
provide accurate relative amounts of the control versus experi-
mental biomarker, only the relative intensity difference.
Isotope-coded affinity-tag-based protein profiling
While both MALDI-MS-based disease biomarker discovery
and DIGE comparatively profile the naturally occurring
forms of peptides and proteins, isotope-coded affinity-tag
(ICAT) analysis profiles the relative amounts of cysteine-
containing peptides derived from tryptic digests of protein
extracts. Because only a single tryptic peptide is needed to
quantify the expression of the corresponding parent
protein, the ICAT reagent utilizes a thiol protein-reactive
group that attaches both a biotin tag and either nine 12C
(light) or nine 13C (heavy) atoms to each cysteine residue.
Following derivatization of the control protein extract with
[12C]-ICAT reagent and the experimental extract with [13C]-
ICAT reagent, the pooled samples are subjected to trypsin
digestion followed by both cation and avidin chromatography.
Liquid chromatography and tandem mass spectrometry
(LC/MS/MS) is then used to identify ICAT peptide pairs
and to quantify the relative 12C/13C ratios. It is important to
note that the ICAT approach provides the relative expres-
sion ratios of individual proteins under two conditions; it
does not provide absolute protein concentrations, nor does
it provide the ratio of the concentration of one protein rela-
tive to another in a single condition. A nice feature of this
approach is that the in vitro incorporation of a stable
isotope into one of the two samples being compared obvi-
ates the need to separately analyze the control and experi-
mental samples by MS. Although a tryptic digest of a
whole-cell human protein extract might produce more than
500,000 peptides, less than 100,000 of these might be
expected to contain cysteine, but based on a search of the
SwissProt database [17], less than 5% of human proteins
lack cysteine and would therefore be missed (that is, more
than 95% of proteins would include at least one cysteine-
containing peptide). 
ICAT results are analogous to those obtained by the use of
two different fluorescent dyes in DNA microarray analysis of
mRNA levels or DIGE analysis of protein expression. The
largest number of proteins profiled so far using this
approach with a single sample are the 491 proteins con-
tained in microsomal fractions of naive and in vitro differen-
tiated human myeloid leukemia cells [18].
Multidimensional protein identification technology 
Multidimensional protein identification technology
(MudPit) is similar to ICAT in that it utilizes cation-
exchange prefractionation followed by reverse-phase (RP)
high-performance liquid chromatography (HPLC) separa-
tion and MS/MS analysis [19]. In contrast to the ICAT
approach, however, MudPit analyzes the entire mixture of
tryptically digested proteins and utilizes tandemly coupled
(cation-exchange followed by reverse-phase) columns. A
specific subset of peptides is eluted from the cation-
exchange column, using a step gradient of increasing salt
concentration, onto the front of the RP column. Peptides are
then eluted from the RP column and enter the mass spec-
trometer for analysis. After the RP gradient is complete, the
next step of the salt gradient releases another subset of pep-
tides from the cation-exchange column onto the RP column,
and the process repeats itself. Using this approach on the
yeast proteome, Wolters et al. [19] identified 5,540 unique
peptides from 1,484 proteins and demonstrated a dynamic
range of detection of 10,000-fold. This method has been
extended to comparative protein profiling by using in vivo
14N/15N metabolic labeling [20,21]. Washburn et al. [20]
used Saccharomyces cerevisiae grown in both 14N- and 15N-
containing minimal media, and 2,264 peptides and 872 pro-
teins were uniquely identified. Also, accurate 14N/15N
quantitation was determined for each peptide with an
average standard deviation of 30%.
Comparison of mRNA and protein levels
Even with the significant developments in the technologies
used to quantify protein abundance over the past couple of
years, protein identification and quantification still lags
behind the high-throughput experimental techniques used
to determine mRNA expression levels. Yet, while mRNA
expression values have shown their usefulness in a broad
range of applications, including the diagnosis and classifica-
tion of cancers [22,23], these results are almost certainly
only correlative, rather than causative; in the end it is most
probably the concentration of proteins and their interactions
that are the true causative forces in the cell, and it is the cor-
responding protein quantities that we ought to be studying.
Primarily because of a limited ability to measure protein
abundances, researchers have tried to find correlations
between mRNA and the limited protein expression data, in
the hope that they could determine protein abundance
levels from the more copious and technically easier mRNA
experiments. Alternatively, if there is definitively no corre-
lation between mRNA and protein data, both quantities
could be used as independent sources of information for use
in machine-learning algorithms, for example, to predict
protein interactions. To date, there have been only a
handful of efforts to find correlations between mRNA and
protein expression levels, most notably in human cancers
and yeast cells; for the most part, they have reported only
minimal and/or limited correlations. 
One of the earliest analyses of correlation looked at 19 pro-
teins in the human liver. Anderson and Seilhamer [24]
found a somewhat positive correlation of 0.48. Another
limited analysis, of the three genes MMP-2,  MMP-9  and
TIMP-1 in human prostate cancers, showed no significant
relationship [25]. An additional cancer study [26] showed a
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Genome Biology 2003, 4:117significant correlation in only a small subset of the proteins
studied. Conversely, Orntoft et al. [27] found highly signifi-
cant correlations in human carcinomas when looking at
changes in mRNA and protein expression levels.
Protein and mRNA correlations in yeast
Many of the present efforts at correlating mRNA and protein
expression have been conducted in yeast using two-dimen-
sional electrophoresis techniques. In particular, Gygi et al.
[7] found that even similar mRNA expression levels could be
accompanied by a wide range (up to 20-fold difference) of
protein abundance levels, and vice versa. These results con-
trast with those of Futcher et al. [28], who found relatively
high correlations (r = 0.76) after transforming the data to
normal distributions. In a previous analysis [29], we merged
the data from both of these datasets (referred to as 2DE-1 [7]
and 2DE-2 [28]), comparing the resulting new larger protein
abundance set (‘merged data-set 1’) with a comprehensive
mRNA expression dataset. The mRNA expression reference
set was constructed through iteratively combining, in a non-
trivial fashion, three sets that used Affymetrix chips and a
SAGE dataset [29]. Using these reference datasets, we were
able to do an all-against-all comparison of mRNA and
protein expression levels, in addition to a number of analy-
ses comparing protein and mRNA expression using smaller,
but broad categories [29,30].
Given the difficult, laborious, and limiting nature of two-
dimensional electrophoresis analysis, many of the newer
protein abundance determinations have been done using
MudPit and derivative technologies. Washburn et al. [31]
used MudPit to analyze and detect 1,484 arbitrary proteins:
they were able to detect a somewhat random sampling of
proteins independent of abundance, localization, size or
hydrophobicity (we refer to this dataset as MudPit-1). In a
further experiment, the authors, comparing expression ratios
for both proteins and mRNA levels, found that although they
could not find correlations for individual loci, they could find
overall correlations when looking at pathways and com-
plexes of proteins that functioned together [21]. Peng et al.
[32] analyzed 1,504 yeast proteins with a false-positive rate -
misidentification of a protein - of less than 1% (we refer to
this dataset as MudPit-2). In their analysis [32], they con-
trasted their methodology with that of Washburn et al. [31]
with which there was significant overlap of proteins. 
A new merged dataset
Expanding upon our previous merged dataset, we con-
structed a new merged dataset (merged data set-2) using the
two two-dimensional electrophoresis and two MudPit
datasets described above. Succinctly (more information is
available on our website at [33]), we transformed each of the
protein-abundance datasets into more quantitative data by
fitting each protein dataset individually onto the reference
mRNA expression dataset. The MudPit-1 dataset was also
fitted onto the more finely grained MudPit-2 dataset. Each
of the new, fitted datasets was then inversely transformed
back into protein space. These derived protein datasets were
then combined into a larger reference dataset; when we had
more than one abundance value for an open reading frame
(ORF), we chose the value from the dataset according to a
prescribed quality ranking (see Figure 1). The resulting set
contained protein abundance information for approxi-
mately 2,000 ORFs. (One caveat with the MudPit data:
while quantitative analysis can be subsequently done on the
results of MudPit experiments, MudPit data alone are only
semi-quantitative, in that the number of peptides deter-
mined is relative to the actual protein abundance within the
cell [31]. Some may therefore argue that MudPit alone is not
optimal for a comparison with mRNA data. Nevertheless,
we feel that our methodical merging process creates a quan-
titative and representative dataset that can be compared
with the mRNA expression data.) Using the resulting data
we could compare mRNA expression and protein abundance
globally (Figure 1a) as well as looking at smaller, broad cate-
gories, such as function or localization (see Figure 1b,c). In
particular, we show that some localization categories - for
example, the nucleolus - have significantly higher correlations
than the global correlation. Other localizations may present
less of a correlation between mRNA and protein data - for
example, the mitochondria - possibly reflecting the heteroge-
neous nature and function of the latter organelle. In terms of
MIPS functional categories [34,35], we show that although
some categories, such as cell rescue, show a lower correlation
than the whole merged set, other functional categories, such
as cell cycle, show a significant increase in correlation. Logi-
cally, this increased correlation reflects the co-regulated
nature of the proteins in this functional category.
Reasons for the absence of correlation
There are presumably at least three reasons for the poor
correlations generally reported in the literature between the
level of mRNA and the level of protein, and these may not be
mutually exclusive. First, there are many complicated and
varied post-transcriptional mechanisms involved in turning
mRNA into protein that are not yet sufficiently well defined
to be able to compute protein concentrations from mRNA;
second, proteins may differ substantially in their in vivo half
lives; and/or third, there is a significant amount of error and
noise in both protein and mRNA experiments that limit our
ability to get a clear picture [36,37].
Examining the first option - that there are a number of
complex steps between transcription and translation - we
looked at correlations between mRNA and protein abun-
dance for those ORFs that had varied or steady levels of
mRNA expression over the course of the cell cycle [38]. To
normalize for the varied degrees of expression for different
ORFs, we took the standard deviation divided by the average
expression level as representative of the variation of each
ORF over the course of the yeast cell cycle (Figure 2).
Broadly speaking, the cell can control the levels of protein at
117.4 Genome Biology 2003, Volume 4, Issue 9, Article 117 Greenbaum et al. http://genomebiology.com/2003/4/9/117
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Logically, we would assume that those ORFs that show a
large degree of variation in their expression are controlled at
the transcriptional level - the variability of the mRNA
expression is indicative of the cell controlling mRNA expres-
sion at different points of the cell cycle to achieve the result-
ing and desired protein levels. Thus we would expect, and we
found, a high degree of correlation (r = 0.89) between the
reference mRNA and protein levels for these particular
ORFs; the cell has already put significant energy into dictating
the final level of protein through tightly controlling the
mRNA expression, and we assume that there would then be
minimal control at the protein level. In contrast, those genes
that show minimal variation in their mRNA expression
throughout the cell cycle are more likely to have little or no
correlation with the final protein level; the cell would be con-
trolling these ORFs at the translational and/or post-transla-
tional level, with the mRNA levels being somewhat
independent of the final protein concentration. And indeed,
we found only minimal correlation between protein and
mRNA expression for these ORFs (r = 0.2).
Furthermore, we found that those ORFs that have higher
than average levels of ribosomal occupancy - that is that a
large percentage of their cellular mRNA concentration is
associated with ribosomes (being translated) - have well cor-
related mRNA and protein expression levels (Figure 2).
These cases probably represent a situation wherein the cell,
having significantly controlled the mRNA expression to
produce a specific level of protein, will probably not also
employ mechanisms to control the translation. Alternatively,
those proteins that have very low occupancy rates have
uncorrelated mRNA and protein expression; thus, given that
the cell has not tightly controlled the mRNA expression for
this ORF, it will dictate the resulting protein levels through
rigorous controls of its translation (that is, through tight
limits on occupancy) [39]. 
A second option for a general lack of correlation between
mRNA and protein abundance may be that proteins have very
different half-lives as the result of varied protein synthesis and
degradation. Protein turnover can vary significantly depending
on a number of different conditions [40]; the cell can control
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Figure 1
Comparison of mRNA expression and protein abundance. (a) A plot
comparing our mRNA reference expression set [29] with our newly
compiled protein abundance dataset. The mRNA axis is in copies per cell;
the protein axis is in thousand copies per cell. The protein dataset is the
result of iteratively fitting two MudPit datasets (MudPit-1 [32] and MudPit-2
[31]) and two two-dimensional electrophoresis datasets (2DE-1 [7] and
2DE-2 [28]). Given the semi-quantitative nature of the MudPit data [31], we
transformed the data into a more quantitative set by fitting each set
individually onto our reference mRNA expression dataset. In addition, we
fit the MudPit-1 dataset onto the more finely-grained MudPit-2 dataset.
Each of the datasets was then moved back into ‘protein space’ using an
inverse transformation derived from the 2DE-1 set, as this set has the most
precise values. These datasets were then combined into the new reference
abundance dataset. In cases in which there were overlapping values for a
given ORF we used the dataset in accord with the following ordering: 2DE-
1, 2DE-2, MudPit-2, MudPit-1. The resulting reference protein abundance
dataset (N = 2044) had a correlation of 0.66 with the mRNA reference
dataset. (b,c) Additionally, we show that when looking at specific subsets
(subcellular localization [52] or functional groups [34,35]) we can find both
higher and lower correlations amongst these groups. The lower
correlations are generally reflective of a more heterogeneous category.
This analysis indicates that while correlations may be weak when looking at
the global data, we tend to find higher correlations when looking at smaller
well-defined subsets of ORFs. Further analysis is available at [33].the rates of degradation or synthesis for a given protein, and
there is significant heterogeneity even within proteins that have
similar functions [41]. Recent efforts have been made to com-
putationally measure these rates [42]. 
Simplistically, it can be presumed that the change in a pro-
tein’s concentration over time will be equal to the rate of
translation minus the rate of degradation. By analogy to con-
cepts in chemical kinetics, we can approximate this equa-
tion: dP(i,t)/dt  =  SE(i,t) - DP(i,t), where P  is protein
abundance i at time t, E is the mRNA expression level of
protein P, S is a general rate of protein synthesis per mRNA,
and D is a general rate of protein degradation per protein
[43]. Additionally there are some experimental methods that
can also be used to measure turnover and the translational
control of protein levels [41-44]. 
Given the degenerate nature of the genetic code, there are
many synonymous codons (codons that translate into the same
amino acid). As the cell is biased in its usage of synonymous
codons - that is, the usage of a subset of codons results in a
higher level of mRNA expression, possibly as a result of
differing cellular tRNA levels [45] - the codon adaptation index
(CAI), a measurement of codon usage, can be used to predict
the expression of a gene [46] (we recently calculated new para-
meters for this model, with some improvement in predictive
strength [47]). It is thought that the CAI will correlate differ-
ently with mRNA levels than with protein abundance levels
due, in part, to protein turnover rates [48]. Ranking the ORFs
in terms of their CAI value, we found that although those ORFs
that ranked the highest in terms of CAI did not show a very
strong correlation between mRNA and protein levels, they nev-
ertheless showed a significantly higher correlation than ORFs
that were ranked as having the lower CAI values (r = 0.48
versus 0.02). The low correlations reflect the fact that the CAI
will correlate differently for protein and mRNA values because
of the additional cellular controls on protein translation,
namely the effect of protein turnover rates. Nevertheless, the
sizable difference in correlations between the two groups of
ORFs with high- and low-ranking CAI values (Figure 2) shows
that there is some relationship between mRNA and protein
values, possibly indicating that highly expressed genes tend to
result in a more correlated level of protein abundance than
lower expressed ones.
Correlations have been found between the mRNA expression
levels of different protein subunits within protein complexes
[49]. This implies that there should be, in general, a correla-
tion between mRNA and protein abundance, as these sub-
units provide a special case as they have to be available in
stoichiometric amounts of proteins for the complexes to func-
tion. Thus, we believe that a major limitation to finding corre-
lations is the degree of natural and manufactured systematic
noise in mRNA and protein expression experiments. There is
a continued effort to both describe and reduce this noise [50].
Meanwhile, in an attempt to get around the noise one could
look at broad categories of proteins - for example, groups
defined by function, structure, or localization - such that the
background noise is cancelled out to some degree [29].
Although proteomics is still in its infancy, given the pace of
technological advancement in protein quantification, mRNA
expression analysis and noise reduction, more comprehensive
correlation studies will soon be feasible. This will allow for
more robust analyses of the relationship between mRNA
expression and protein abundance values. Finally, to be fully
able to understand the relationship between mRNA and
protein abundances, the dynamic processes involved in protein
synthesis and degradation have to be better understood; is the
protein level changing because of a change in the rate of protein
synthesis, or mRNA, or protein turnover? These questions
need to be looked into further before we can appreciate in full
the relationship between mRNA and protein abundance levels.
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Figure 2
The differences in correlation between mRNA and protein expression
values using novel categories. We see significant differences when looking
at the highest and lowest ranking of groups of ORFs in the following
categories: occupancy, CAI (codon adaptation index) value [45-47] and
variability. Occupancy refers to the percentage of transcripts associated
with ribosomes; we compared the correlation between the top 100 ORFs
and the bottom 100 in terms of occupancy (r =0.78 versus 0.30). For the
CAI, we compared the correlation between mRNA and protein for those
ORFs with the highest CAI and those with the lowest (r = 0.48 versus
0.02). Variability refers to the normalized standard deviation (that is, the
standard deviation divided by the average expression level) for all ORFs in
the cell-cycle expression dataset of Cho et al. [38]. Here, we compared
the correlations between protein abundance and mRNA expression for
the most variable compared with the least variable proteins (r = 0.89
versus 0.20). We found significant differences between the correlations of
mRNA and protein levels for the top and bottom ranking populations for
each of the comparisons.
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